newsfilter
← Latest News
PR Newswire·

Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights

TYRA
  • Tyra Biosciences reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients, showing a 79% overall response rate & 64% complete response rate at 60 mg QD.
  • The company completed a $400 million financing in September 2026 to advance its dabogratinib 3x3 strategy through late-stage development.
  • Cash, cash equivalents, & marketable securities totaled $700.5 million as of September 30, 2026, providing a runway through 2030.
  • The Phase 2 IR NMIBC study (SURF302) demonstrated 100% overall response rate in patients with single marker lesions, supporting a planned Phase 3 adjuvant study expected to initiate in 2027.
  • Phase 2 LG-UTUC study (SURF303) reported its first participant achieving a complete response at 60 mg QD, with additional results expected in 2027.
  • Phase 2 achondroplasia study (BEACH301) opened a sixth dose level following favorable safety data in the safety sentinel cohort, with initial results expected in 2027.
  • Third quarter R&D expenses were $43.1 million, driven by clinical trial activities & headcount growth, compared to $25.5 million in the same period of 2025.
  • General & administrative expenses rose to $11.7 million in the third quarter of 2026 from $7.5 million in 2025 due to increased personnel costs.
  • The company reported a third quarter net loss of $51.1 million, compared to $29.9 million in the same period of 2025.
  • Dabogratinib remains the lead candidate in three Phase 2 trials targeting LG-UTUC, low-grade IR NMIBC, & achondroplasia, with Orphan Drug Designation granted for achondroplasia.
Company
Tyra Biosciences
Keywords
Tyra Biosciences